| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PITTSBURGH—MylanInc. announced that its subsidiary, Mylan PharmaceuticalsInc., has filed suit against the U.S. Food and Drug Administration (FDA) in theU.S. District Court for the District of Columbia seeking to overturn a decisionby FDA, which awarded Teva Pharmaceutical Industries Ltd. sole 180-day exclusivity for the generic version ofits affiliate Cephalon's Provigil. 
 
The complaint alleges that Teva did not maintainvalid paragraph IV (PIV) certifications as a result of its acquisition ofCephalon. The complaint states that, once Teva became the owner of Cephalon,Teva could no longer infringe its own patents through a PIV certification andthat Teva therefore is not entitled to exclusivity based on patentcertifications. Mylan also alleges that FDA should have found that Mylan is thesole first filer on one of the Orange Book Patents for Provigil, that Tevaabandoned its abbreviated new drug application (ANDA), and that FDA should haveapproved Mylan's ANDA for this product. Mylan is seeking an immediate orderfrom the Court entitling it to exclusivity and immediate approval for its ANDA.
 
 
The complaint also alleges that FDA's decision,which blocks Mylan and other generic entrants from launching their genericProvigil products, is unlawful. Mylan has indicated that it believes the Federal Trade Commission didnot contemplate the current outcome when it imposed its conditions on theTeva/Cephalon merger.
 
Mylan is seeking immediate equitable relief fromthe court requiring FDA to approve Mylan's ANDA.
 
 
According to IMS Health, Provigil had U.S. salesof approximately $1.1 billion for the 12 months ending Dec. 31, 2011.
 


About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue